ATAI Life Sciences N.V. Common Shares (ATAI)
ATAI Life Sciences N.V. is a biotechnology company focused on developing psychedelics and other psychoactive compounds for mental health treatment. Based in the Netherlands, it aims to advance innovative therapies for psychiatric and neurological disorders through research and clinical development.
Company News
atai Life Sciences received a multi-year, milestone-driven grant from NIDA to develop novel non-hallucinogenic 5-HT2A/2C receptor agonists for treating opioid use disorder, focusing on innovative drug discovery approaches.
Atai Life Sciences reported Q2 2025 financial results with mixed performance, including revenue of $0.72 million, reduced net loss of $27.7 million, and continued progress in mental health treatment drug development, with a strategic combination with Beckley Psytech planned.
Several biotechnology firms have psychedelic treatments in development, with promising results from clinical trials. The psychedelic market is expected to grow significantly, and most investors are favorable towards psychedelic stocks.
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, ...Full story available on Benzinga.com
Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors? Let's find out.